On Monday, Candel Therapeutics Inc (NASDAQ: CADL) was -4.96% drop from the session before settling in for the closing price of $5.95. A 52-week range for CADL has been $1.56 – $14.60.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales slid by -20.00% over the last five years. When this article was written, the company’s average yearly earnings per share was at 13.60%. With a float of $34.58 million, this company’s outstanding shares have now reached $46.93 million.
The firm has a total of 38 workers. Let’s measure their productivity. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Candel Therapeutics Inc (CADL) Insider Activity
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Candel Therapeutics Inc stocks. The insider ownership of Candel Therapeutics Inc is 26.79%, while institutional ownership is 33.94%. The most recent insider transaction that took place on Mar 18 ’25, was worth 396,995. In this transaction Chief Medical Officer of this company sold 45,316 shares at a rate of $8.76, taking the stock ownership to the 52,493 shares. Before that another transaction happened on Mar 18 ’25, when Company’s Chief Scientific Officer sold 32,146 for $8.76, making the entire transaction worth $281,673. This insider now owns 96,527 shares in total.
Candel Therapeutics Inc (CADL) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.26 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 13.60% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 16.34% during the next five years compared to -43.86% drop over the previous five years of trading.
Candel Therapeutics Inc (NASDAQ: CADL) Trading Performance Indicators
You can see what Candel Therapeutics Inc (CADL) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 2.77.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.75, a number that is poised to hit -0.37 in the next quarter and is forecasted to reach -1.87 in one year’s time.
Technical Analysis of Candel Therapeutics Inc (CADL)
Analysing the last 5-days average volume posted by the [Candel Therapeutics Inc, CADL], we can find that recorded value of 1.48 million was better than the volume posted last year of 1.25 million. As of the previous 9 days, the stock’s Stochastic %D was 5.33%. Additionally, its Average True Range was 0.77.
During the past 100 days, Candel Therapeutics Inc’s (CADL) raw stochastic average was set at 17.24%, which indicates a significant increase from 6.03% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 99.79% in the past 14 days, which was lower than the 164.42% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $8.14, while its 200-day Moving Average is $6.72. Now, the first resistance to watch is $5.79. This is followed by the second major resistance level at $5.93. The third major resistance level sits at $6.11. If the price goes on to break the first support level at $5.47, it is likely to go to the next support level at $5.29. Should the price break the second support level, the third support level stands at $5.15.
Candel Therapeutics Inc (NASDAQ: CADL) Key Stats
There are 47,235K outstanding shares of the company, which has a market capitalization of 266.88 million. As of now, sales total 0 K while income totals -55,180 K. Its latest quarter income was 0 K while its last quarter net income were -14,070 K.
